Researchers from Eli Lilly studying the mechanism of action of the investigational compound raloxifene have discovered a new pathway through which estrogen affects various organs, according to an article in the journal Science. Their findings may have important physiological implications for women, particularly their skeletal and cardiovascular health.
In a statement, Lilly notes that researchers have, for several decades, acknowledged the benefits of estrogen in protecting women from cardiovascular disease, osteoporosis and, more recently, Alzheimer's disease. However, they have also warned against the potential increase in breast and uterine cancer, and throughout this period have searched for an explanation of why estrogen affects various organs of the body so differently.
Raloxifene Studies In studies conducted with raloxifene, a drug that counters estrogen action in the breast while mimicking it in the bone, the Lilly team, led by molecular biologist Na Yang, has discovered a possible explanation of how the same drug may cause different effects, depending upon which tissue it is acting, and how the natural hormone itself manages to adopt so many different guises, according to Science.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze